Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

nib (PCI-32765) Monotherapy Demonstrates Long-term Safety and Durability of Response in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Leukemia (SLL) Patients in an Open-Label Extension Study
Susan O'Brien, M.D., Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

A long-term analysis of Phase 1/2 studies of single agent ibrutinib in 148 patients with CLL/SLL aimed to evaluate safety based on time on therapy, summarize safety findings in both the treatment-naive and relapsed/refractory (R/R) populations and assess overall response rate (ORR) and duration of response (DOR). The results showed that the percentage of patients who experienced a grade 3 or higher serious adverse event (SAE) declined over time from 43% within the first year of study treatment to 32% after the first year of treatment. Grade 3 or higher adverse events (AEs) and SAEs considered to be related directly to ibrutinib also declined notably compared to the first year of treatment: 24% and 8%, respectively, to 7% and 0%. The most frequent grade 3 or higher adverse events regardless of relationship to study drug were pneumonia (16.9%), hypertension (13.5%), neutropenia (11.5%), thrombocytopenia (7.4%) and diarrhea (5.4%).

Based on these patients the ORR was determined at 80.6% for treatment-naive patients, and 83.8% for R/R patients. The ORR plus partial response with lymphocytosis was 87.1% in the treatment-naive population and 88.9% in the R/R population. Median DOR was not reached in either population. At 30 months, 95.8% of treatment-naive and 69.7% of R/R responders were alive without disease progression.

-ORAL PRESENTATION- CLL Abstract #675:
Ibrutinib In Combination With Rituximab (iR) is Well Tolerated and Induces a High Rate of Durable Remissions in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial I
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... NEW YORK , July 7, 2015 ... new generation of drugs within human and veterinary oncology, ... the Securities and Exchange Commission, in connection with the ... the NASDAQ Stock Market. The number of American Depositary ... price range for the offering have not yet been ...
(Date:7/7/2015)... July 7, 2015  Monopar Therapeutics LLC, an emerging ... that its co-founder and CEO, Chandler D. Robinson ... U.K. Alumni Entrepreneurial Award. The British Council selected one ... India , and the ... made by entrepreneurs who have leveraged their U.K. education ...
(Date:7/7/2015)... DIEGO , July 7, 2015   ... announced today initiation of enrollment and dosing of ... study of ABX-1431, a first-in-class, investigational endocannabinoid system ... platform, which finds new small molecule drug candidates ... enzymes with important regulatory roles in human physiology ...
Breaking Medicine Technology:Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 2Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 3
... SUNNYVALE, Calif., Oct. 19, 2011 ... premier radiation oncology company, announced today that it ranked 274th ... growing technology, media, telecommunications, life sciences and clean technology companies ... based on percentage fiscal year revenue growth from 2006 to ...
... therapy games can help people with Parkinson,s disease improve their ... by the UCSF School of Nursing and Red Hill Studios, ... the subjects in the three-month research project showed small improvements ... and Red Hill were the first research team in the ...
Cached Medicine Technology:Accuray Ranked 274th Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2Accuray Ranked 274th Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3Accuray Ranked 274th Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 4Red Hill Studios and UCSF Announce Computer Games Help People with Parkinson's Disease 2Red Hill Studios and UCSF Announce Computer Games Help People with Parkinson's Disease 3
(Date:7/7/2015)... ... July 07, 2015 , ... Greatist today announced the ... helps active people find the most fun activities to do with friends. , The ... It also increases Greatist’s opportunity for events, e-commerce, and brand partnerships. , “I’ve been ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today ... to access its antibody combination therapy (ACT) technology platform. The platform has ...
(Date:7/7/2015)... ... July 07, 2015 , ... Healthpointe is proud to announce ... an anesthesiologist and pain management specialist, will be evaluating and treating patients with orthopedic ... , After receiving his Bachelor of Science in Biology from the University of the ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... telemedicine programs in communities throughout Georgia, announces the launch of the first ambulance ... communities of Hancock County, GA. The new program will not only provide more ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... explosive environments with the introduction of the Nightstick XPP-5422GM , the world’s ... magnets, one at its base and one on its clip. The new Nightstick ...
Breaking Medicine News(10 mins):Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 3
... one touch away with the American Heart Association,s new Pocket ... , This is the association,s first iPhone application. Users ... anywhere. First aid instructions are available even when out of ... application is available for download at Apple,s iTunes store. The ...
... recession and associated job cuts is creating a decrease ... health insurer growth and pressuring profitability, according to a ... , "Conning projects that health care costs will increase ... through 2011," said Terence Martin, analyst at Conning Research ...
... July 9 According to Millennium Research Group (MRG), ... ongoing economic crisis is putting pressure on publicly-funded health ... cardiology (IC) device prices in the region. MRG,s ... 2009 (Part II) report details the extent to ...
... July 9 MAQUET Cardiovascular ... a new contract with Novation, one of the health ... terms of this agreement, MAQUET Cardiovascular US Sales LLC ... Provista customers with its Cardiac Assist counterpulsation system, including ...
... Pa., July 9 Universal Health Services, Inc. (NYSE: ... voted to pay a cash dividend of $0.08 per share ... September 1, 2009. , , Universal Health Services, Inc. ... its subsidiaries, acute care and behavioral health hospitals, and ambulatory ...
... There,s a new company in the U.S. to help sick ... carrying out this mission everywhere. , , Three ... and portable oxygen, to grooming and sickroom and bathroom equipment, ... getting around. , , The company has a mission ...
Cached Medicine News:Health News:American Heart Association Launches First iPhone Application: First Aid and CPR Information Within Pocket's Reach 2Health News:Conning Research: Health Insurance Industry Premium Growth and Profitability Under Pressure Through 2011 2Health News:European Health Care Institutions Forced to Select Lower-Priced Interventional Cardiology Devices 2Health News:MAQUET Cardiovascular Awarded New Contract by Novation 2
Facial Mask...
Deluxe Abdominal Binders...
CDIs Abdominal Binders are designed with a non-pitching, body contouring, non-rolling elastic band that provides both support and compression. Available in 9, 12 and 15 widths with waist ranges from ...
Ideal for abdominal and flank procedures....
Medicine Products: